| Pair Name | Nobiletin, Palbociclib | ||
| Phytochemical Name | Nobiletin (PubChem CID: 72344 ) | ||
| Anticancer drug Name | Palbociclib (PubChem CID: 5330286 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Nobiletin, Palbociclib | |||
| Disease Info | [ICD-11: 2C90.0] | Renal cell carcinoma | Investigative | |
| Biological Phenomena | Induction-->Blockade of cell cycle in G0/G1 phase | |||
| Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Down-regulation | Phosphorylation | CDK2 | hsa1017 | |
| Down-regulation | Expression | CDKN1A | hsa1026 | |
| Down-regulation | Expression | PSMD9 | hsa5715 | |
| Down-regulation | Phosphorylation | RB1 | hsa5925 | |
| Down-regulation | Expression | SKP2 | hsa6502 | |
| In Vivo Model | A total of 2×10⁶ 786-O cells were mixed 1:1 with Matrigel (BD Biosciences) in a total volume of 200 μL, and were injected subcutaneously into the right flank side of nude mice. | |||
| Result | Nobiletin downregulates the SKP2-p21/p27-CDK2 axis to inhibit tumor progression and shows synergistic effects with palbociclib on renal cell carcinoma | |||
| No. | Title | Href |
|---|---|---|
| 1 | Nobiletin downregulates the SKP2-p21/p27-CDK2 axis to inhibit tumor progression and shows synergistic effects with palbociclib on renal cell carcinoma. Cancer Biol Med. 2021 Feb 15;18(1):227-244. doi: 10.20892/j.issn.2095-3941.2020.0186. | Click |
